Products Categories
CAS No.: | 486-16-8 |
---|---|
Name: | carbinoxamine |
Article Data: | 6 |
Molecular Structure: | |
Formula: | C16H19 Cl N2 O |
Molecular Weight: | 290.793 |
Synonyms: | Pyridine,2-[p-chloro-a-[2-(dimethylamino)ethoxy]benzyl]-(7CI,8CI); (?à)-Carbinoxamine;2-[p-Chloro-a-[2-(dimethylamino)ethoxy]benzyl]pyridine;Carbinoxamine; McN-R 73Z; Paracarbinoxamine; Paracarinoxamine |
EINECS: | 207-628-6 |
Density: | 1.143g/cm3 |
Boiling Point: | 381.1°Cat760mmHg |
Flash Point: | 184.3°C |
PSA: | 25.36000 |
LogP: | 3.40260 |
Molecular Structure of Carbinoxamine (CAS NO.486-16-8):
IUPAC Name: 2-[(4-Chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine
Molecular Formula: C16H19ClN2O
Molecular Weight: 290.79
EINECS: 207-628-6
Mol File: 486-16-8.mol
Melting Point: < 25 °C
Index of Refraction: 1.562
Molar Refractivity: 82.55 cm3
Molar Volume: 254.4 cm3
Surface Tension: 43 dyne/cm
Density: 1.143 g/cm3
Flash Point: 184.3 °C
Enthalpy of Vaporization: 62.93 kJ/mol
Boiling Point: 381.1 °C at 760 mmHg
Vapour Pressure: 5.21E-06 mmHg at 25 °C
Canonical SMILES: CN(C)CCOC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
InChI: InChI=1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3
InChIKey: OJFSXZCBGQGRNV-UHFFFAOYSA-N
Classification Code: Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Neurotransmitter Agents
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
mouse | LD50 | intravenous | 18mg/kg (18mg/kg) | U.S. Army Armament Research & Development Command, Chemical Systems Laboratory, NIOSH Exchange Chemicals. Vol. NX#00940, |
Carbinoxamine (CAS NO.486-16-8), its Synonyms are (+-)-Carbinoxamine ; 2-(p-Chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine ; Allergefon ; Carbinoxamina ; Carbinoxaminum ; McN-R 73Z ; Paracarbinoxamine ; Ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-N,N-dimethyl- (9CI) ; N,N-Dimethyl-2-(p-chloro-alpha-(2-pyridyl)benzyloxy)ethylamine ; Pyridine, 2-(p-chloro-alpha-(2-(dimethylamino)ethoxy)benzyl . It is antihistamine and anticholinergic.
Carbinoxamine is approved by the U.S. Food and Drug Administration (FDA) for hay fever (a.k.a. allergic rhinitis, SAR and PAR); vasomotor rhinitis; mild urticaria; angioedema, dermatographism and allergic conjunctivitis. At present, all carbinoxamine-containing formulations are approved only for adults or children ages 3 or older.